Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Barrett's oesophagus: better left alone?

R Lambert1

  • 1International Agency for Research on Cancer, Lyon, France. lambert@iarc.fr

European Journal of Gastroenterology & Hepatology
|July 4, 2001
PubMed
Summary

The risk of oesophageal adenocarcinoma in Barrett's oesophagus patients is often overestimated. Surveillance is generally not needed unless high-risk factors like reflux and smoking are present in males with good health.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using magnetic resonance imaging to characterize pedicle asymmetry in both normal patients and patients with adolescent idiopathic scoliosis.

Spine·2004
Same author

Implementing Colorectal Cancer Screening: Group 2 Report. ESGE/UEGF Colorectal Cancer--Public Awareness Campaign. The Public/Professional Interface Workshop: Oslo, Norway, June 20 - 22, 2003.

Endoscopy·2004
Same author

Diagnosis of esophagogastric tumors.

Endoscopy·2004
Same author

A model for the efficacy of combined inhibitors.

Journal of applied microbiology·2003
Same author

Magnification and chromoscopy with the acetic acid test.

Endoscopy·2003
Same author

Treatment of esophagogastric tumors.

Endoscopy·2003

Area of Science:

  • Gastroenterology
  • Oncology
  • Medical Research

Background:

  • Barrett's oesophagus is a risk factor for oesophageal adenocarcinoma.
  • Current risk estimations in publications and meta-analyses may be inflated.

Discussion:

  • The overall risk is estimated at 0.5 per 100 patients annually, equating to one cancer per 200 patients yearly.
  • Many patients with Barrett's oesophagus have comorbidities or are elderly, impacting management decisions.
  • Management hinges on index endoscopy findings; dysplasia necessitates strict observation or treatment.

Key Insights:

  • Endoscopic surveillance for early neoplasia detection is often unjustified in patients without dysplasia.
  • A select group of male patients with good performance status and risk factors (reflux history, smoking) may benefit from surveillance.
  • Risk stratification is crucial for appropriate patient selection.

Outlook:

  • Refining risk stratification models can optimize surveillance strategies.
  • Further research may clarify the precise risk-benefit ratio for surveillance in specific Barrett's oesophagus patient subgroups.
  • Personalized management approaches are essential for this patient population.

Related Experiment Videos